Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2745-2751

  Saliba, Faouzi ^a   Hagipantelli, Rachel ^a   Misset, Jean Louis ^a   Bastian, Gérard ^a   Vassal, Gilles ^a   Bonnay, Marc ^a   Herait, Patrice ^a   Cote, Carole ^a   Mahjoubi, Mondher ^a   Mignard, Dominique ^a   Cvitkovic, Esteban ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETORPHAN; ALPHA 1 ANTITRYPSIN; CAMPTOTHECIN DERIVATIVE; CARBOXYLESTERASE; DNA TOPOISOMERASE; ENKEPHALINASE INHIBITOR; FECES LIPID; FLUOROURACIL; FOLINIC ACID; GASTRIN; GLUCAGON; IRINOTECAN; LEVAMISOLE; LOPERAMIDE; OXALIPLATIN; PROSTAGLANDIN E2; SOMATOSTATIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; XYLOSE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLON BIOPSY; COLON MUCOSA; COLON SECRETION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FECES ANALYSIS; FECES CULTURE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE TRANSIT TIME; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031926749     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2745     Document Type: Article

References (40)

1. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
2. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-{4-(1-piperidino)-1-piperidino} carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
3. Masuda N, Fufuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
4. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
5. Futatsuki K, Wakui A, Nakao I, et al: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 21:1033-1038, 1994
6. Wagener DJT, Verdonk HER, Dirix LY, et al: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6:129-132, 1995
7. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
8. Takeuchi S, Dobashi K, Fujimoto S, et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother 18:1681-1689, 1991
9. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: A new derivative camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990
10. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
11. Rothenberg BM, Eckardt J, Kuhn J, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
12. Conti BJ, Kemeny N, Saltz L, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
13. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
14. Rothenberg ML, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
15. Clavel M, Extra JM, Abigerges D, et al: French phase I studies of CPT-11 using 3 different schedules of administration. Ann Oncol 3:197, 1992 (suppl 5; abstr)
16. Abigerges D, Chabot G, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
17. Abigerges D, Armand JP, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
18. Sakata Y, Suzuki H, Kamataki T: Preventive effect of TJ-14, a kampo (chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11). Jpn J Cancer Chemother 21:1241-1244, 1994
19. Gandia D, Abigerges D, Armand JP, et al: CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11:196-197, 1993
20. Lestingi TM, Yokes EE, Gray W, et al: A phase I trial of CPT-11 in solid tumors with G-CSF and antidiarrheal support. Proc Am Soc Clin Oncol 14:1563, 1995 (abstr).
21. Awouters F, Megens A, Verlinden M, et al: Loperamide: Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 38:977-995, 1993
22. Llorens C, Gacel G, Swerts JP, et al: Rational design of enkephalinase inhibitors: Substrate specficity of enkephalinase studied from inhibitory potency of various dipeptides. Biochem Biophys Res Commun 96:1710-1716, 1980
23. Lecomte JM, Costentin J, Vlaiculescu A, et al: Pharmacological properties of acetorphan, a parenterally active enkephalinase inhibitor. J Pharmacol Exp Ther 237:937-944, 1986
24. Baumer Ph, Danquechin-Dorval E, Bertrand J, et al: Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhea. Gut 33:753-758, 1992
25. Roge J, Baumer P, Berard H, et al: The enkephalinase inhibitor, acetorphan, in acute diarrhea: A double-blind, controlled clinical trial versus loperamide. Scand J Gastroenterol 28:352-354, 1993
26. Urien S: Micropharm, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharm Res 12:1225-1230, 1995
27. Eherer A, Fordtran J: Fecal osmotic gap and pH in experimental diarrhea of various causes. Gastroenterology 103:545-551, 1992
28. Shiau YF, Feldman G, Resnick M, et al: Stool electrolytes and osmolality measurements in the evaluation of diarrheal disorders. Ann Intern Med 102:773-775, 1985
29. Canal P, Gay C, Dezuze A, et al: For the pharmacology and molecular mechanisms group of the European organization for research and treatment of cancer. Pharmacokinetics and Pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688-2695, 1996
30. Cascinu S: Drug therapy in diarrheal diseases in oncology/hematology patients. Crit Rev Oncol Hematol 18:37-50, 1995
31. Beaugerie L: Toxicité intestinale des médicaments (estomac et duodénum exclus). Encycl Méd Chir (Elsevier, Paris), Gastroenterologie 9-100-A-15:1-11, 1996
32. Takasuna K, Kasai Y, Kitano Y, et al: Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Nippon Yakurigaku Zasshi 105:447-460, 1995
33. Ikuno N, Soda H, Watanabe M, et al: Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87:1876-1883, 1995
34. Hughes S, Higgs NB, Turnberg LA: Loperamide has antisecretory activity in the human jejunum in vivo. Gut 25:931-935, 1984
35. Burleigh D: Loperamide but not morphine has anti-secretory effects in human colon, in vitro. Eur J Pharmacol 202:277-280, 1991
36. Catimel G, Chabot GG, Guastalla JP, et al: Phase I pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995
37. Fujimori A, Hoki Y, Popescu NC, et al: Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol Res 8:295-301, 1996
38. Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972-974, 1992
39. Kudoh S, Fukuoka M, Masuda N, et al: Relationship between the pharmacokinetics of irinitecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer 86:406-413, 1995
40. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151, 1995